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Abstract
Markers of Alzheimer’s disease (AD) are being widely sought with a number of studies suggesting blood measures of
inflammatory proteins as putative biomarkers. Here we report findings from a panel of 27 cytokines and related proteins in
over 350 subjects with AD, subjects with Mild Cognitive Impairment (MCI) and elderly normal controls where we also have
measures of longitudinal change in cognition and baseline neuroimaging measures of atrophy. In this study, we identify five
inflammatory proteins associated with evidence of atrophy on MR imaging data particularly in whole brain, ventricular and
entorhinal cortex measures. In addition, we observed six analytes that showed significant change (over a period of one year)
in people with fast cognitive decline compared to those with intermediate and slow decline. One of these (IL-10) was also
associated with brain atrophy in AD. In conclusion, IL-10 was associated with both clinical and imaging evidence of severity
of disease and might therefore have potential to act as biomarker of disease progression.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
and although progress is being made, the development of disease
modification therapies is currently hampered by the lack of
biomarkers. There are many potential types of biomarkers, but in
particular, indicators of disease progression or disease state would
find utility in clinical trials, to stratify participants or to measure
change over time [1–3]. Currently, cerebrospinal fluid (CSF) levels
of tau and amyloid beta (Ab) are the most reliable and widely used
protein markers for AD. However, there are practical drawbacks
of using CSF as a sample medium, in addition to poor correlation
between the protein levels and disease severity [4]. Several other
potential protein-based AD markers have been explored during
the past decade [5], these markers have most often been analyzed
in relation to diagnosis rather than disease severity or clinical
progression. In addition to fluid biomarkers, neuroimaging
measures, including hippocampal volume analysis, have become
widely used in clinical trials [6].
Considerable evidence suggests that inflammation plays a role
in the pathogenesis of AD [7,8], and the central nervous system
(CNS) contains many components of the immune system that are
synthesized by astrocytes, microglia and neurons [9,10]. Fibrillar
Ab deposition is associated with the activation of microglia [10–
12], itself a relatively early event in the pathogenesis of AD, and
the formation of the Ab/microglia complex in early stages of AD
has been reported to precede extensive tau-related neurofibrillary
pathology [4,13,14]. The immune response of the brain is
orchestrated by microglial cells which, on activation, become
phagocytes and secrete a wide range of inflammatory mediators,
including cytokines and chemokines, growth factors, complement
molecules and adhesion molecules [15]. An increased interest in
the complex network of cytokines has identified a growing number
of inflammatory cytokines involved in CNS disorders, with a
number of studies identifying cytokine proteins able to predict
clinical AD diagnosis with high accuracy [16–18].
Our aim was to investigate the inflammatory response to AD in
plasma samples and to examine whether plasma cytokines are
associated with disease severity or disease progression. We
analyzed a panel of 27 cytokines in a cohort of 351 patients with
neuroimaging data available using multiplex immunoassays. The
cytokine profiles of AD, MCI and control cases were compared,
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evaluated with respect to neuroimaging measures and to rate of
decline.
Materials and Methods
AddNeuroMed Cohort
Samples used came from the AddNeuroMed study, a cross-
European cohort for biomarker discovery. In this cohort, AD cases
were assessed with a range of measures, including clinical at three
monthly intervals in the first year and annually thereafter. MCI
and control groups were assessed annually. The disease duration
of AD cases were provided by their doctors, families and carers.
All subjects were white Europeans recruited from the UK, France,
Italy, Finland, Poland and Greece. The full standardized
assessment in these studies includes demographic and medical
information, cognitive assessment including the Mini-Mental State
Examination (MMSE), Alzheimer’s Disease Assessment Scale –
cognitive (ADAS-Cog), Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) battery, and scales to assess
function, behaviour and global levels of severity including the
Clinical Dementia Rating (CDR) scale. The cohort has been
previously described in [19,20].
Informed consent was obtained from all subjects according to
the Declaration of Helsinki (1991) and protocols and procedures
were approved by the relevant Institutional Review Board at each
collection site. All participants, or their carers where capacity was
compromised and gave written consent or assent according to the
laws of the relevant country. The capacity for consent was assessed
by a clinician with experience in capacity assessment in the context
of dementia. Exclusion criteria included other neurological or
psychiatric disease, significant unstable systemic illness or organ
failure and alcohol or substance misuse.
Subjects
A total of 351 subjects were selected for this analysis grouped
into 3 categories: 112 control subjects, 122 MCI patients and 117
AD patients. A second time point for biochemical analysis in
relation to the progression of disease was used for this study (one
year follow-up from baseline) with sample available from 104 of
the 117 AD patients. The age range for subjects in the AD, MCI
and control group were comparable (Table 1).
MMSE and CDR assessments were available from all 351
subjects, and ADAS-cog assessment was performed in AD patients
only.
Sample Preparation and Data Acquisition
All participants were required to fast for two hours before blood
sample collection; only water or fluids containing no milk or sugar
were allowed during the fasting period. Plasma samples were
collected using EDTA coated tubes and centrifuged at 3000 rpm
for 8 minutes at 4uC before being aliquoted and then frozen at
280uC.
Plasma samples were analyzed with a multiplex suspension
array system using Bioplex Luminex 200 instrument (Bio-Rad
Laboratories, Hercules, CA). The panel (Bio-Plex Human cytokine
27–Plex) consisted of the following 27 cyto- and chemokines:
Interleukin (IL)-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9,
IL-10, IL-12 (p70), IL-13,IL-15, IL-17, Eotaxin, fibroblast growth
factor (FGF) basic, granulocyte-colony stimulating factor (G-CSF),
granulocyte-macrophage colony stimulation factor (GM-CSF),
Interferon-gamma (IFN-c), interferon-inducible protein-10 (IP-
10), monocyte chemotactic protein-1 (MCP-1), macrophage
inflammatory protein (MIP)-1a, MIP-1b, platelet-derived growth
factor (PDGF)-BB, Rantes, tumor necrosis factor (TNF)-a and
vascular endothelial growth factor (VEGF). The overall detection
concentration range according to the standard curves was 6,560–
82,807 pg/ml.
The samples were prepared according to the manufacturer’s
instructions. All samples and standards were run in duplicate and
were measured as pg/ml. The system running protocol was set
according to manufacturer’s guidelines: the protocol was set to a
high RP1 (fluorescent channel) target value for CAL2 calibration
and the acceptable recovery percent range to a range of 80–120%.
The protocol was set to 100 beads per region and the sample
volume adjusted to 50 ml. After the plate reading, the results files
were generated using Bio-Plex Manager software 4 (Bio-Rad
Laboratories, Hercules, CA).
Table 1. Demographic and clinical parameters of AD patients, MCI and control subjects.
Variables Controls MCI AD
Baseline N=112 Baseline N=122
Baseline N=117
Year follow up N=104
Gender (F/M) 60/52 60/62 78/39 (baseline)
70/34 (year follow up)
Age, (mean, SD)* 72.3, (6.72) 73.9, (5.63) 76.2, (6.09)
MMSE score (median), (±SD) ¥ 29, (1.21) 27, (1.64) 20.37, (4.68)
CDR score (median), (±SD) ? 0, (0.09) 0.5, (0.05) 1, (0.48)
ADAS-cog score (mean), (±SD) N/A N/A 24.9, (9.97)
APOe4 allele presence N= 32 N=35 N= 59 (baseline)
N= 50 (year follow up)
Key:
MMSE =Mini-Mental State Examination; CDR=Clinical Dementia Rating; ADAS-cog =Alzheimer’s Disease Assessment Scale-cognitive subscale; Year follow up= a year
follow up from baseline.
SD = Standard Deviation.
*ANOVA F= 5.72 (2,329); p = 0.0036. Scheffe test: Control v MCI p = 0.480; Control v AD p=0.004; MCI v AD p= 0.107.
¥ANOVA F= 221.29 (2,328); p,0.001. Scheffe test: Control v MCI p,0.001; Control v AD p,0.001; MCI v AD p,0.001.
?ANOVA F= 1320.56 (2,214) p,0.0001. Scheffe test: Control v MCI p,0.001; Control v AD p,0.001; MCI v AD p,0.001.
doi:10.1371/journal.pone.0064971.t001
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Data Processing
Some samples duplicate measures were excluded from further
analysis. The exclusion was based on the observed concentration
of standards that were not within the 80–120% recovery range. In
order to screen outliers, we generated a correlation matrix with
each subject for all 27 analytes. This gave us an output in the form
of a correlation coefficient. Patients falling below an r = 0.8
correlation coefficient threshold were omitted from subsequent
analysis.
Neuroimaging
Six different 1.5 T MR systems (4 General Electric, 1 Siemens
and 1 Picker) were used for data collection. Data acquisition was
designed to be compatible with the Alzheimer Disease Neuroim-
aging Initiative (ADNI) [21]. The imaging protocol was based on
using a high resolution saggital 3D T1-weighted MPRAGE
volume (voxel size 1.161.161.2 mm3) and axial proton density/
T2-weighted fast spin echo images. Full brain and skull coverage
was required and a detailed quality control was carried out on all
MR images according to the AddNeuroMed quality control
procedure [20,22]. All MR images were examined by an on-site
radiologist for exclusion of any subjects with non-AD related
pathologies.
MR Image Analysis
The highly automated Freesurfer pipeline (version 4.5.0) was
used to produce both regional cortical thickness measures and
regional volume measures. Cortical reconstruction and volumetric
segmentation included removal of non-brain tissue, automated
Talairach transformation, intensity correction and segmentation of
the subcortical white matter and deep gray matter volumetric
structures (including hippocampus, amygdala, caudate, putamen,
ventricles). Identification of the grey matter/white matter bound-
ary was followed by surface inflation and registration to a spherical
atlas which utilises individual cortical folding patterns to match
cortical geometry across subjects and parcellation of the cerebral
cortex into units based on gyral and sulcal structure. All regional
volume measures from each subject were normalised by the
subjects’ intracranial volume. Cortical thickness measures were
used in their raw form.
Statistical Analysis
Statistical analysis was performed in SPSS Version 15 (SPSS
Inc., Chicago, USA) and STATA 10 (Stata Corporation, College
Station, TX, USA). The Kolmogorov-Smirnov test was used to
check for normal distribution of continuous outcomes. In cases of
non-normality the natural log of each variable was used. Linear
regression was used in order to compare baseline (visit 1) plasma
cytokine levels between AD, MCI and control samples adjusting
for age, gender, centre and presence of the APOe4 allele. Multiple
linear regression was also employed to investigate the relationship
of neuroimaging measures, such as whole brain volume, hippo-
campus and entorhinal cortex with baseline cytokine levels
adjusting for age, gender, centre, presence of the APOe4 allele
and disease status. Linear regression was also performed to assess
the relationship of covariates (Table S1). To test whether the
association of cytokines with disease status differed between
subjects in different APOe4 allele or gender strata, or whether
the association of neuroimaging measures with cytokines was
different amongst disease groups, we tested for interactions
followed by likelihood ratio tests to compare a model assuming
no interaction to a model with an interaction term. If significant
interactions were identified, data was presented separately for
different strata. Differences were considered significant if p#0?05
(two-tailed).
Figure 1. Association between inflammatory proteins levels
measured in plasma versus ventricular volume. Scatter diagram
with regression lines show the relationship between proteins levels of
IL-1ra (N = 86) (figure 1A), IL-6 (N = 83) (figure 1B) and IL-10
(N = 38)(figure 1C)and ventricular volume in the three separate
diagnostic groups. Keys: Blue line and dots denote control samples;
orange line and dots denote MCI samples; red line and dots denote AD
samples; brown dotted line denotes 95% CI.
doi:10.1371/journal.pone.0064971.g001
Inflammatory Response in Alzheimer’s Disease
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e64971
Association of Cognitive Decline with Changes in
Cytokine Levels
AD patients were grouped into slow, intermediate and fast
declining patients, based on cognitive decline slope per year in
MMSE, ADAS-cog and CDR. Cognitive decline slopes were
calculated using mixed linear effects models. The average baseline
cognitive outcome and the average change in the cognitive
outcome over follow-up time was calculated for all subjects per day
as a group (fixed effects) and subject-specific intercept and slope
terms which reflected deviation from the group average (mixed
linear effects) were calculated. The calculation included adjust-
ment for age at baseline, disease duration at baseline, gender,
cholinesterase inhibitors, antidepressants, antipsychotics, ethnici-
ty/centre, education, being a widow/er, being in a nursing home
and presence of APOe4 allele. Covariates significant at the p,0.10
level were included in a final model for each cognitive model. The
annual cognitive decline was obtained by multiplying the slope of
cognitive decline measured using days with the average number of
days per year (365.25). An annual MMSE, ADAS-cog and CDR
score decline of 4 or more was considered as fast decline, whereas
an annual MMSE score decline of 2–4 was considered as
intermediate decline; and a score below 2 was considered as slow
decline.
To assess change in cytokines as a function of cognition in
people with dementia, we measured cytokines in subjects with AD
at year 1 as well as at baseline. Mixed linear mixed effects models
as described above were used to investigate the relationship
between changes in cytokine levels measured at baseline and at
year 1 and cognitive decline in AD. As before, the calculation
included adjustment for age at baseline, disease at baseline,
gender, cholinesterease inhibitors, antidepressants, antipsychotics,
ethnicity/centre, education, being a widow/er, being in a nursing
home and presence of APOe4 allele. Only age at baseline, disease
duration, centre and gender were robustly associated with cytokine
changes between the two visits and were therefore used as
covariates. A significant interaction between the cognitive decline
group and the variable indicating when cytokine levels were
Table 4. Summary statistics for the multiple linear regression model assessing the relationship between inflammatory proteins
and brain MRI measures (whole brain volume and left entorhinal cortex).
Cytokine Whole cohort Controls MCI AD
(pg/ml) Beta 95% CI p value Beta (R2) 95% CI p value Beta 95% CI p value Beta 95% CI p value
(R2) (R2) (R2)
WTNF-a 20.005 20.011 0.081 20.001 20.01 0.754 20.003 20.014 0.613 20.01 20.02 0.047*
20.008 0.001 (20.042) 0.007 20.002 0.008 20.04 7.80E-03
EIL-13 21.00E-04 26.50E-05 0.171 4.10E-04 24.80E-05 0.389 21.20E-05 9.10E-05 0.351 29.00E-05 21.80E-04 0.048*
20.005 3.30E-05 20.008 1.30E-04 20.01 6.70E-05 20.048 4.70E-06
The relationship between cytokines and MRI measures was assessed by multiple linear regression adjusting for age, gender, collection site and presence of the APOe4
allelle. Whole cohort result shows the model overall data and was based on all three diagnostic groups with 239 subjects for TNF-a and 241 subjects for IL-13.
Key: Beta = regression coefficient (slope) on transformed data; CI = 95% confidence interval; R2 = R2 value (coefficient of determination) after adjusting for covariates;
*p,0.05; W indicates whole brain volume (normalized to Intracranial Volume (ICV)); E indicates left entorhinal cortex(normalized to Intracranial Volume (ICV)).
doi:10.1371/journal.pone.0064971.t004
Table 3. Summary statistics for the multiple linear regression model assessing the relationship between inflammatory proteins
and ventricular volume.
Cytokine Whole cohort Controls MCI AD
(pg/ml) Beta 95% CI p value Beta (R2) 95% CI p value Beta (R2) 95% CI p value Beta (R2) 95% CI p value
(R2)
IL-1ra 2.00E-04 20.002 0.77 0.003 20.001 0.099 0.002 20.001 0.223 20.003 20.006 0.021*
(20.008) 0.001 20.032 0.006 20.013 0.004 20.068 28.80E-04
IL-6 20.001 20.003 0.151 22.10E-03 20.004 0.904 0.001 20.002 0.405 20.005 20.009 0.018*
20.033 0.001 20.028 0.004 20.016 0.004 20.101 20.001
IL-10 20.001 20.003 0.431 21.10E-03 20.004 0.809 0.001 20.004 0.805 20.006 20.011 0.028*
(20.031) 0.001 20.031 0.003 20.059 0.005 20.103 20.001
Whole cohort presents results for the whole cohort and was based on all three diagnostic groups with 255 subjects for IL-1ra, 250 subjects for IL-6 and 128 subjects for
IL-10.
The relationship between cytokines and MRI measures was assessed by multiple linear regression adjusting for age, gender, collection site and presence of the APOe4
allelle.
Key: Beta = regression coefficient (slope) on log- transformed data; 95% CI = 95% confidence interval; R2 = R2 value (coefficient of determination) after adjusting for
covariates;
*p,0.05; Ventricular Volume is normalized to Intracranial Volume (ICV).
doi:10.1371/journal.pone.0064971.t003
Inflammatory Response in Alzheimer’s Disease
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e64971
measured (visit) would indicate differences between the change in
cytokine levels and decline group.
Results
Exclusions
Four analytes, namely MIP-1a, MIP-1b, RANTES (CCL5) and
VEGF, were excluded from analysis as more than 50% of the
subjects fell below an r = 0.8 correlation coefficient threshold
suggesting technical failure. In average, across the remaining 23
analytes a range of 1–14 subjects were excluded from analysis, as
they fell below the r = 0.8 correlation coefficient threshold in the
correlation matrix. The number of excluded subjects was similar
across the three diagnostic groups. The demographics and clinical
parameters of AD patients, MCI and control subjects are
presented in Table 1 and Table 2 shows the results of the 23
detectable proteins in plasma.
Figure 2. Inflammatory proteins levels at Visit 1 (baseline) and Visit 2 (one year follow up from baseline) for the three ADAS-cog
cognitive decline groups. Linear mixed effects models indicated significant yearly changes in the log-transformed IL-2 (figure 2A), IL-4 (figure 2B),
IL-10 (figure 2C), G-CSF (figure 2D), IFN-c (figure 2E), and PDGF (figure 2F) (pg/ml) inflammatory protein levels between the three cognitive decline
groups, after adjusting for covariates. Slow indicates slow decliner. Inter indicates intermediate decliner. Fast indicates fast decliner Key: 1– Visit
1(Baseline); 2– Visit 2 (one year follow up from baseline).
doi:10.1371/journal.pone.0064971.g002
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Peripheral Cytokine Levels Reflect the Inflammatory
Process Associated with AD
First, in order to evaluate whether a different extent of
inflammation in AD, MCI and controls is reflected in the
respective plasma samples, baseline cytokine levels between the
different groups were compared. The level of FGF (p= 0.012) was
significantly different between AD and control subjects; whereas
Eotaxin (p= 0.045) was significantly different between AD and
MCI (Table 2).
Inflammatory Proteins in Plasma are Associated with
Pathological Severity
Regression analyses were performed to examine the relationship
between inflammatory cytokines and disease severity as measured
by atrophy on MRI measures. We first assessed the relationship
between multiple cytokine levels and neuroimaging measures of
whole brain volume, entorhinal cortex, entorhinal cortex thick-
ness, hippocampal volume and ventricular volume in the whole
data set sample. There was no significant relationship between
multiple cytokine levels and neuroimaging measures except for
TNF-a (p = 0.045), which correlated with left hippocampal volume
(data not shown).
We then examined whether association of cytokines with MRI
measurements differed between the different diagnostic groups.
Significant interactions in the ventricular volume, whole brain
volume and entorhinal cortex were observed between four
cytokines [IL-6 (p= 0.005), IL-10 (p= 0.025), IL-13 (p= 0.028)
and IL-1ra (p = 0.002)] and clinical status (Table S2). Although we
did not observe any associations between these cytokines and
neuroimaging measurements for the whole cohort, significant
associations between these five cytokines and neuroimaging
measures were observed in AD patients (Table 3, 4). Specifically,
three measures (IL-1ra, IL-6 and IL-10) significantly associated
with ventricular volume in AD (Figure 1).
Inflammatory Proteins in Plasma are Associated with Rate
of Cognitive Decline in AD
We then compared changes in the inflammatory signals
between baseline and year 1 visit in participants with different
rates of clinical decline, as measured with the MMSE, ADAS-cog
and CDR. Overall, we observed significant changes in levels of a
number of cytokines between patients with a fast or intermediate
cognitive decline and patients with slow cognitive decline,
particularly measured with the ADAS-cog. Specifically, we found
a significant increase in the levels of IL-4 (p = 0.024), IL-10
Table 5. Summary of longitudinal changes in inflammatory protein levels between cognitive decline groups as measured by
ADAS-cog.
ACTUAL PROTEIN LEVELS (pg/ml) LINER MIXED EFFECTS MODEL
Cytokine Slow Intermediate Fast Slow versus Inter
¥ Slow versus fast¥
ADAS-Cog
Decliners
ADAS-Cog
Decliners
ADAS-Cog
Decliners
Mean (SD) [N] Mean (SD) [N] Mean (SD) [N]
(pg/ml) Baseline Year 1 Baseline Year 1 Baseline Year 1 Beta 95% CI p value Beta 95% CI p value
IL-2 11.73 9.64 9.82 11.86 19.45 12.17 0.105 0.021* 20.511
213.27 28.09 29.09 27.74 239.57 269.55 0.691 1.278 0.086 0.683 0.777
[77] [83] [44] [47] [23] [22]
IL-4 3.11 3.02 2.78 3.54 2.9 3.96 0.074 0.016* 0.051
(1.31) 21.77 21.73 21.72 21.55 22.33 0.392 0.713 0.387 0.729 0.024*
[114] [91] [64] [51] [31] [24]
IL-10 11.38 7.69 14.17 10.45 7.59 9.39 20.654 0.724 0.037
28.81 27.65 2145.96 218.1 26.24 26.2 0.143 0.941 0.825 1.627 0.040*
[54] [67] [29] [37] [16] [18]
G-CSF 76.76 58.79 72.21 61.81 65.4 68.8 20.036 0.084 0.006
238.1 228.14 236.83 226.26 230.52 239.29 0.265 0.564 0.316 0.627 0.046*
[112] [89] [63] [49] [31] [24]
IFN-c 209.12 241.6 178.56 270.62 235.41 319.21 0.086 0.018* 20.069
2241.6 2146.43 2222.89 2132.29 (334.19) 2194.33 0.493 0.908 0.347 0.774 0.102
[116] [91] [65] [51] [33] [24]
PDGF 3135.09 2536.81 2422.27 2823.29 3149.69 3628.44 0.065 0.031* 20.057
21969.2 22481.5 22079.5 22769.5 22760.1 23668.9 0.731 1.399 0.62 1.3 0.073
[111] [85] [64] [46] [32] [23]
The relationship between change in cytokine levels over one year and AD cognitive decline group was assessed by mixed effect model adjusting for age, gender, APOe4
allelle, collection site and disease duration. Slow indicates slow decliner. Inter indicates intermediate decliner. Fast indicates fast decliner. Key: Beta = regression
coefficient (slope) on transformed data; 95%CI = 95% confidence interval;N = number of sample; ¥ - coefficients represent the difference in the slopes for the given
cytokine between cognitive decline groups across the two time points (i.e. interaction between time and the rate of decline groups).
*p,0.05.
doi:10.1371/journal.pone.0064971.t005
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(p = 0.040) and G-CSF (p = 0.046) in AD patients with a fast
cognitive decline compared to slow cognitive decline in ADAS-cog
over one year (Figure 2 and Table 5). AD patients with
intermediate cognitive decline showed significantly higher levels
of IL-2 (p = 0.021), IL-4 (p = 0.016), IFN-c (p = 0.018) and PDGF
(p= 0.031) compared to those with slow cognitive decline over one
year (Figure 2 and Table 5).
Discussion
We investigated plasma levels of cytokines in AD, MCI and
control samples to determine whether inflammatory proteins are
associated with disease progression or disease severity as assessed
by memory test scores or by neuroimaging data respectively. AD is
characterized by early memory loss with the first sites of
pathological change measurable in life being the hippocampus
and the entorhinal cortex [23,24]. Around 80–90% of AD subjects
show atrophy in both sites compared to only 5–10% of control
subjects [25,26]. Our study identified a number of analytes that
correlate with brain imaging data - five analytes being associated
with ventricular, whole brain and entorhinal measures of atrophy.
In addition, six analytes were associated with rates of decline in
cognitive scores.
A number of studies have reported that Ab deposition can
activate microglia and induce the production of IL-1, IL-6, TNF-a
and MCP-1 in the AD brain [7,27–32]. Ab-induced secretion of
IFN-c and IL-1b has also been observed [33]. Grammas & Ovase
demonstrated a high level of production of IL-1b, IL-6, MCP-1
and TNF-a in AD brain microvessels compared to control [34].
McGeer & Zhao showed IL-10 can be produced by microglia
[35,36]. Moreover, Soares’s study observed an elevation of IL-13
level was associated with APOe4 allele; a known risk factor for AD
[37]. The elevation of these inflammatory proteins in AD brain
microvessels suggest that these proteins may play a role in
neuronal damage.
Our study finds IL-6, TNF-a and three addition analytes (IL-
1ra, IL-10 and IL-13) in plasma significantly inversely correlated
with ventricular volume, whole brain volume or entorhinal cortex
in AD. Furthermore, we observe an increase in the level of IL-10
between visit 1 and visit 2 in ADAS-cog fast decliners compare to
slow decliners and, an increase level of IFN-c was observed
between visit 1 and visit 2 in ADAS-cog intermediate decliners
compared to slow decliners.
Plasma cytokines are known to communicate with the brain
[38] and circulating levels of peripheral cytokines have been
shown to correlate and reflect central cytokine levels in the brain
[38,39]. An important but unanswered question regards the source
of the inflammatory signature in the periphery in AD – is it
independent of, or secondary to, the inflammatory reaction in the
brain? There are various routes whereby an inflammatory activity
may communicate between brain and the periphery [38]. One of
these routes involves diffusion of cytokines between blood and
brain in regions with an impaired blood brain barrier (BBB). In
some cases cytokines can be actively transported across the BBB
[39]. Another route involves cytokine activation of the endothe-
lium signalling to macrophages in brain [40]. Understanding
which, if any of these mechanisms underlies the peripheral
signature of inflammatory proteins in AD is an important topic for
further investigation.
The current, and these earlier studies show clearly that there is
an inflammatory change in the brain in AD and an inflammatory
signal in the periphery although how these are connected and the
exact nature of the inflammatory profile are both far from certain.
However, although it is clear from this and from other studies that
there is a peripheral inflammatory response in AD, the question
remains as to whether it might be sufficiently robust to act as a
biomarker. One study reported 18 plasma proteins that could
predict clinical AD diagnosis with high accuracy [16]. A
bioinformatics-based follow-up showed that reducing the panel
to 5 proteins improved accuracy to 96% [41]. However, this
finding has not been widely replicated. Individual cytokines found
by Ray et al, are also reported in other studies – for example, IL-6
and TNF-a associated with cognitive decline [42]. Our multiplex
assay included only two (TNF-a and G-CSF) of the 18 proteins
described by Ray et al but we do find G-CSF to be associated with
decline on cognitive tests and to be significantly different between
slow and fast declining AD patients. G-CSF plays an interesting
role in the inflammatory response in AD as it suppresses the
production or activity of proinflammatory cytokines [43]. A recent
investigation showed decreased plasma G-CSF levels in early AD
[44], in contrast to the finding of Ray et al. In the current study we
find a significantly higher expression of G-CSF in fast compared to
slow declining AD patients.
One limitation of the current study is that no adjustment of
multiple testing was performed. However, given the modest effect
sizes observed, correction for multiple testing whilst performing
such large number of analyses beyond looking for associations
between cytokines and AD status (such as rate of decline, measures
of disease in the brain and change in time of the analytes in
relation to disease progression) would require study sizes
considerably larger than ours, and probably any existing
biomarker cohort currently existing. We draw from this two
conclusions - first that the data presented here should be
considered preliminary and requiring replication and secondly,
that as in genomic studies, cohorts for biomarker analyses will
have to increase substantially. Nonetheless, this study is one of the
first to examine large numbers of functionally related analytes in a
large cohort of subjects in relation to multiple measures of disease
severity. Moreover, our finding of an association between an
inflammatory profile including some markers previously associated
with AD, suggests that the inflammatory change in the periphery
does occur in AD and is worthy of further investigation and in
particular that IL-2, IL-4, IL-10, G-CSF and IFN-c may be
markers not of disease per se but of disease severity.
Supporting Information
Table S1 Association between inflammatory proteins
and covariates. Most proteins showed a significant association
with the covariate of collection site, with the exception of IL9,
IL10, IL15 and IP-10. The number of proteins showing a
significant association with the covariates of age and gender was
very low (N= 2 and N=1 respectively). *p,0.05; **p,0.001.
(DOC)
Table S2 Summary of significant interaction between
inflammatory proteins and diagnostic groups. The
relationship between cytokines and MRI measures in diagnostic
groups was assessed by linear regression adjusting for age, gender,
collection site and presence of the APOe4 allelle. *p,0.05;
**p,0.01.
(DOC)
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